SCHEMBL25786992

SCHEMBL25786992

CC(C)(C)NS(=O)(=O)Cn1nnc(-c2ccccc2Nc2ccc(C(C)(F)P)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.39
▸ MAPT P10636 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ TSHR P16473 3/20 0.38
▸ LMNA P02545 7/20 0.38
▸ KMT2A Q03164 6/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ MEN1 O00255 4/20 0.37
▸ ABCG2 Q9UNQ0 2/20 0.37
▸ HPGD P15428 3/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ TAS2R14 Q9NYV8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552241 0.93 ABCG2 (0.43) SMN1; SMN2MAPTALDH1A1TSHRLMNA
SCHEMBL25786906 0.81 MAPT (0.47) SMN1; SMN2MAPTALDH1A1LMNAKMT2A
SCHEMBL25787068 0.81 SMN1; SMN2 (0.40) SMN1; SMN2MAPTALDH1A1TSHRLMNA
SCHEMBL25787163 0.80 KDM4E (0.52) SMN1; SMN2MAPTALDH1A1TSHRLMNA
SCHEMBL25786917 0.80 SMN1; SMN2 (0.47) SMN1; SMN2MAPTALDH1A1LMNAKMT2A
SCHEMBL25787116 0.80 DDX3X (0.40) SMN1; SMN2MAPTALDH1A1TSHRLMNA
SCHEMBL21749246 0.80 ABCG2 (0.45) SMN1; SMN2MAPTALDH1A1TSHRLMNA
SCHEMBL25787051 0.79 SMN1; SMN2 (0.39) SMN1; SMN2MAPTALDH1A1TSHRLMNA
SCHEMBL20552814 0.79 ABCG2 (0.44) SMN1; SMN2MAPTALDH1A1LMNAKMT2A
SCHEMBL25787152 0.76 DDX3X (0.43) SMN1; SMN2MAPTALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 SMN1; SMN2 3035/4885MAPT 516/4885ALDH1A1 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback